Good clinical practices and its use in primary data in adverse events
Abstract
The good clinical practices are national or international standards for the clinical assays; these practices give credibility and confidence to data given by the stage of the clinical development of the product to be investigated. The adverse event has to be compiled in the primary document with all the characteristics and transcribed to the notebook of data in every subject in the investigation. During the I Clinical Assay, the subject may have symptoms or unfavourable signs with causal relationship with the product or not. Nine clinical records as well as its respective notebooks for data in carriers of the hormone-refractory prosthatic cancer included in the Fase II Clinical assay "Clinical evaluation of the use of the vaccine-chemotherapy -vaccine using the epidermic growing factor in the treatment of these patients were treated in "III Congreso"Pinar del Rio hospital. Statistical analysis methods were used. The most frequent adverse events were: changes in the clinical laboratory tests (100 %), followed by 94% of correspondence in the transcription data of the adverse event into the notebook of data; 94..1% of the events were properly classified and a 92.2% were transcribed properly in the CDR (Revolution Defence Committee).100 per cent of the adverse events had a perception criterion. It is recommended periodical internal monitoring in every CA of the site.Downloads
References
1. Proveyer Derich Samira, Rodríguez Morales Ilys, Ortiz Reyes Rosa María. Ensayos clínicos y buenas prácticas clínicas: una encuesta a especialistas del Instituto Nacional de Oncología y Radiobiología. Rev cubana med [revista en la Internet]. 2003 Ago [citado 2008 marz 01]; 42(4): Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232003000400006&lng=es
2. Royal College of General Practitioners. Good Medical Practice for General Practitioners.[monografía en internet] July 2008. London. Disponible en: http://www.rcgp.org.uk/PDF/PDS_Good_Medical_Practice_for_GPs_July_2008.pdf [citado 2008 marz 01]
3. Stepeh K. Carter. Cancer Clinical trial. Clinical aspects in the design and conduct of phase II tiral. 1996; 223-237
4. Jay Herson. Cancer Clinical trial. Statistical aspect in the design and analysis of fase II Clinical trial; 1999.p.240-256
5. Tannock IF ,etc al. Chemotherapy with Mitosantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative patient. J: Clin. Oncol. 1996;14; 1756-64.
6. Small EJ, Fratesi P; [et al]. Inmunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clinic Oncol. 2000 18: 894-903.
7. Ministerio de Salud pública. Consideraciones acerca de las tendencias generales de los ensayos clínicos en el mundo y su diagnostico en nuestro medio. Habana 29 marzo de 1999. MINSAP
8. Gu G, Yuan J, Wills M, Kasper S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo.Cancer Res. 2007 ;67(10):4807-15.
9. Baselga J, Albanell J, Ruiz A, et al: Phase II and tumor pharmacodynamic study of gefinitib (ZD1839) in patients with advanced breast cancer; 2005.
10. Robinson D.R., Wu YM & Lin S.F., The protein tyrosinekinase family of the human genome. Oncogene. 2007;19. 5548-5557.
11. Miller, DC, Hafez, KS, Stewart, A, et al. "Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base." Cancer 2003; 98:1169.
12. American Dietetic Association; Dietitians of Canada. Position of the American Dietetic Association and Dietitians of Canada: Vegetarian diets. Journal Am Diet Assoc. [revista en la Internet] 2003; [citado] 103(6): 748-65. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/12778049
How to Cite
Issue
Section
License
Authors who have publications with this journal agree to the following terms: Authors will retain their copyrights and grant the journal the right of first publication of their work, which will be publication of their work, which will be simultaneously subject to the Creative Commons Attribution License (CC-BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g.: deposit it in an institutional telematic archive or publish it in a volume). Likewise, and according to the recommendations of the Medical Sciences Editorial (ECIMED), authors must declare in each article their contribution according to the CRediT taxonomy (contributor roles). This taxonomy includes 14 roles, which can be used to represent the tasks typically performed by contributors in scientific academic production. It should be consulted in monograph) whenever initial publication in this journal is indicated. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which may produce interesting exchanges and increase citations of the published work. (See The effect of open access). https://casrai.org/credit/
